What’s Next? Five Things To Look Out For In June

First Ophthalmic Biosimilar To Launch In US; Alvotech Merger To Close

In June, Medicines for Europe will host its annual and legal affairs conferences in Barcelona, while on the commercial side Hikma’s CEO Siggi Olafsson is to resign from the London-listed company.

What's Next Image
June is a busy month for industry • Source: Informa

History is to be made in June with the launch of the first biosimilar anti-VEGF product for ophthalmic conditions in the US: Samsung Bioepis’ Byooviz (ranibizumab-nuna) referencing Genentech’s Lucentis (ranibizumab) blockbuster. (Also see "FDA Approves First Ophthalmic Biosimilar With Samsung Bioepis’ Lucentis Rival" - Generics Bulletin, 20 September, 2021.)

Approved by the FDA in September last year, Byooviz had been expected to begin shipping in the US by the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

The Generics Bulletin Top 50, Part Two: Leading Players Leapfrog The Competition

 
• By 

In the second instalment of Generics Bulletin’s Top 50 ranking for 2025, we see plenty of movement among our mid-table collection of companies.

The Generics Bulletin Top 50, Part One: German Giants Rise Up The Ranks

 
• By 

Two leading German generics and biosimilars giants were the big movers in our top ten ranking of off-patent industry leaders for 2025. We reveal the latest developments among the top players in the first instalment of this year’s Generics Bulletin Top 50.

Just One Week To Go! Entry Deadline Looms For GGB Awards 2025

 
• By 

There is now just one week left to submit entries to the Global Generics & Biosimilars Awards 2025, with the entry deadline set for August 1.

Biocon Biologics ‘Strategically’ Expands Enbrel Biosimilar With A Launch In Australia

 

After acquiring a solid biosimilars business from Viatris, Biocon Biologics has ticked off another market for its Nepexto (etanercept).

More from Products

Just One Week To Go! Entry Deadline Looms For GGB Awards 2025

 
• By 

There is now just one week left to submit entries to the Global Generics & Biosimilars Awards 2025, with the entry deadline set for August 1.

UK Xtandi Patent Stands Strong As Accord, Sandoz, Teva Lose Appeal

 
• By 

The Court of Appeal in London has upheld a key UK patent shielding Astellas’ Xtandi, rejecting claims by a trio of generic drugmakers that it was obvious after finding that the generics firms’ expert analysis was tainted by hindsight.

Biocon Biologics ‘Strategically’ Expands Enbrel Biosimilar With A Launch In Australia

 

After acquiring a solid biosimilars business from Viatris, Biocon Biologics has ticked off another market for its Nepexto (etanercept).